Heartland Group Holdings Valuation
Is HGH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of HGH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: HGH (NZ$1.28) wird unter unserer Schätzung des Fair Value (NZ$2.44) gehandelt.
Deutlich unter dem Marktwert: HGH wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HGH?
Other financial metrics that can be useful for relative valuation.
| What is HGH's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | NZ$856.22m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does HGH's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.5x | ||
CIMBT CIMB Thai Bank | 12.1x | n/a | ฿19.5b |
PNB Philippine National Bank | 1.7x | -14.3% | ₱30.3b |
OAB Oman Arab Bank SAOG | 22x | n/a | ر.ع217.0m |
BJTM Bank Pembangunan Daerah Jawa Timur | 6.1x | n/a | Rp8.9t |
HGH Heartland Group Holdings | 10.1x | 13.9% | NZ$856.2m |
Price-To-Earnings gegen Gleichaltrige: HGH ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (10.1x) mit dem Durchschnitt der anderen Unternehmen (10.2x) vergleicht.
Price to Earnings Ratio vs Industry
How does HGH's PE Ratio compare vs other companies in the Global Banks Industry?
Price-To-Earnings gegen Industrie: HGH ist teuer, wenn man sein Price-To-Earnings Verhältnis (10.3x) mit dem Global Banks Branchendurchschnitt (8.9x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is HGH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 10.4x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von HGH für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NZ$1.22 | NZ$1.48 +21.6% | 21.6% | NZ$1.92 | NZ$1.16 | n/a | 3 |
| Mar ’25 | NZ$1.21 | NZ$1.48 +22.3% | 21.3% | NZ$1.91 | NZ$1.16 | n/a | 3 |
| Feb ’25 | NZ$1.39 | NZ$1.81 +30.0% | 15.5% | NZ$2.19 | NZ$1.53 | n/a | 3 |
| Jan ’25 | NZ$1.48 | NZ$1.81 +22.1% | 15.5% | NZ$2.19 | NZ$1.53 | n/a | 3 |
| Dec ’24 | NZ$1.59 | NZ$1.91 +19.9% | 11.1% | NZ$2.19 | NZ$1.68 | n/a | 3 |
| Nov ’24 | NZ$1.58 | NZ$2.01 +27.4% | 6.9% | NZ$2.19 | NZ$1.85 | n/a | 3 |
| Oct ’24 | NZ$1.78 | NZ$2.06 +15.9% | 4.3% | NZ$2.19 | NZ$2.00 | n/a | 3 |
| Sep ’24 | NZ$1.80 | NZ$2.06 +14.6% | 4.3% | NZ$2.19 | NZ$2.00 | n/a | 3 |
| Aug ’24 | NZ$1.77 | NZ$2.11 +19.0% | 5.6% | NZ$2.27 | NZ$2.00 | n/a | 3 |
| Jul ’24 | NZ$1.70 | NZ$2.11 +23.9% | 5.6% | NZ$2.27 | NZ$2.00 | n/a | 3 |
| Jun ’24 | NZ$1.62 | NZ$2.11 +30.0% | 5.6% | NZ$2.27 | NZ$2.00 | n/a | 3 |
| May ’24 | NZ$1.57 | NZ$2.13 +35.5% | 5.2% | NZ$2.27 | NZ$2.00 | n/a | 3 |
| Apr ’24 | NZ$1.56 | NZ$2.13 +36.3% | 5.2% | NZ$2.27 | NZ$2.00 | NZ$1.28 | 3 |
| Mar ’24 | NZ$1.79 | NZ$2.14 +19.6% | 4.5% | NZ$2.27 | NZ$2.04 | NZ$1.21 | 3 |
| Feb ’24 | NZ$1.81 | NZ$2.13 +17.5% | 4.2% | NZ$2.25 | NZ$2.04 | NZ$1.39 | 3 |
| Jan ’24 | NZ$1.80 | NZ$2.08 +15.7% | 6.7% | NZ$2.25 | NZ$1.91 | NZ$1.48 | 3 |
| Dec ’23 | NZ$1.84 | NZ$2.08 +13.2% | 6.7% | NZ$2.25 | NZ$1.91 | NZ$1.59 | 3 |
| Nov ’23 | NZ$1.75 | NZ$2.13 +21.5% | 4.2% | NZ$2.25 | NZ$2.04 | NZ$1.58 | 3 |
| Oct ’23 | NZ$1.66 | NZ$2.13 +28.1% | 4.2% | NZ$2.25 | NZ$2.04 | NZ$1.78 | 3 |
| Sep ’23 | NZ$1.81 | NZ$2.22 +22.5% | 6.0% | NZ$2.36 | NZ$2.04 | NZ$1.80 | 3 |
| Aug ’23 | NZ$2.09 | NZ$2.23 +6.5% | 13.2% | NZ$2.53 | NZ$1.74 | NZ$1.77 | 4 |
| Jul ’23 | NZ$1.91 | NZ$2.23 +16.5% | 13.2% | NZ$2.53 | NZ$1.74 | NZ$1.70 | 4 |
| Jun ’23 | NZ$2.11 | NZ$2.23 +5.5% | 13.2% | NZ$2.53 | NZ$1.74 | NZ$1.62 | 4 |
| May ’23 | NZ$2.30 | NZ$2.25 -2.2% | 11.2% | NZ$2.53 | NZ$1.84 | NZ$1.57 | 4 |
| Apr ’23 | NZ$2.28 | NZ$2.23 -2.1% | 10.5% | NZ$2.46 | NZ$1.84 | NZ$1.56 | 4 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.